Clinical Trials Logo

Alpha1-antitrypsin Deficiency clinical trials

View clinical trials related to Alpha1-antitrypsin Deficiency.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05899673 Enrolling by invitation - Clinical trials for Alpha1-Antitrypsin Deficiency

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Start date: August 8, 2023
Phase: Phase 3
Study type: Interventional

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-alpha-1 antitrypsin (Z-AAT) protein. People who are currently taking part in or have completed previous fazirsiran studies (AROAAT2001 [NCT03945292] or AROAAT2002 [NCT03946449]) can continue to receive fazirsiran in this study. Participants will receive fazirsiran every 3 months for almost 2 years and will then be followed for an additional 6 months. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.